- In ENESTfreedom, 51.6% of eligible first-line Tasigna patients maintained TFR for 48 weeks after stopping treatment; study did not meet its statistical primary endpoint, specifically the > 50% lower limit of the 95% confidence interval
- ENESTop met primary endpoint with 57.9% of eligible patients who had switched to Tasigna from Glivec maintaining TFR for 48 weeks after treatment cessation
- First results from clinical program provide greater understanding of TFR and may help establish appropriate criteria for eligible Ph+ CML patients to stop treatment
- Novartis expresses its deepest gratitude to the patients who participated in these important clinical trials
Slingshot members are tracking this event:
Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|NVS||Community voting in process|
Slingshot Insights Explained
Jun 04, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Tfr, Tasigna, Ph+ Cml Patients